Home › Compare › CIHPF vs ABBV
CIHPF yields 8.00% · ABBV yields 3.06%● Live data
📍 CIHPF pulled ahead of the other in Year 1
Combined, CIHPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CIHPF + ABBV for your $10,000?
CB Industrial Product Holding Berhad, an investment holding company, manufactures and sells palm oil mill equipment and related spare parts in Indonesia, Malaysia, Papua New Guinea, Central America, Africa, Liberia, and internationally. The company operates through Plantation and Milling, Equipment and Engineering, Refinery, Special Purpose Vehicles, and Investing segments. Its products include screw presses, digesters, sludge centrifuges, and king crackers. The company also cultivates oil palm; and engages in trading and processing crude palm oil, crude palm kernel oil, sludge palm oil, and refined bleached deodorized palm oil. In addition, it is involved in designing, fabricating, manufacturing, retrofitting, and maintaining works of various special purpose vehicles, such as firefighting and rescue vehicles, and ambulances. Further, the company designs, manufactures, installs, tests, commissions, and maintains works of boilers and unfired pressure vessels. Additionally, it engages in the provision of services for engineering support, mechanical fabrication, commissioning, and other contracting works for palm oil mills; trading of palm oil mill processing equipment; supply and sale of spare parts for palm oil mills; and design, fabrication, supply, procurement, maintenance, and service of aviation related equipment. CB Industrial Product Holding Berhad was founded in 1980 and is based in Shah Alam, Malaysia.
Full CIHPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.